Pfizer

Please use landscape view or desktop screen to view the content.

Signs and Symptoms That May Present in ATTR-CM^1-14

Transthyretin Amyloid Cardiomyopathy > Raising Suspicion of ATTR-CM > Raising Suspicion > Signs and Symptoms of ATTR-CM

Cardiovascular

Heart failure
Intolerance to standard HF
therapies
Low voltage relative to LV
thickness
Echocardiography showing
increased LV wall thickness
Pseudoinfarct pattern on ECG
Cardiac arrhythmia
Aortic stenosis

Nervous System

AUTONOMIC

Neuropathy
Diarrhea/Constipation
Orthostatic hypotension
Erectile dysfunction

PERIPHERAL

Peripheral sensory motor
dysfunction
Peripheral neuropathy

Ocular

Vitreous opacity
Glaucoma
Scalloped pupils

Musculoskeletal/Orthopedic

Biceps tendon rupture
Lumbar spinal stenosis
Carpal tunnel syndrome
Hip/Knee arthroplasty

Renal

Renal impairment
Cardiorenal syndrome

Expand all Expand all

ATTR-CM: Transthyretin amyloid cardiomyopathy; ECG: Electrocardiology; HF: Heart failure; LV: Left ventricular.

References:

Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types.
Curr Opin Cardiol. 2018;33(5):571-579.
Narotsky DL, Castano A, Weinsaft JW, Bokhari S, Maurer MS. Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging. Can J Cardiol. 2016;32(9):1166.e1-1166.e10.
Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017;135(14):1357-1377.
Brunjes DL, Castano A, Clemons A, Rubin J, Maurer MS. Transthyretin Cardiac Amyloidosis in Older Americans. J Card Fail.
2016;22(12):996-1003.
Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28(1):10-21.
Maurer MS, Hanna M, Grogan M, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161-172.
González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope.
Rev Esp Cardiol (Engl Ed). 2017;70(11):991-1004.
Reynolds MM, Veverka KK, Gertz MA, et al. Ocular Manifestations of Familial Transthyretin Amyloidosis. Am J Ophthalmol. 2017;183:156-162.
Rubin J, Alvarez J, Teruya S, et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: Can we identify affected patients earlier?. Amyloid. 2017;24(4):226-230.
Dang J, Abulizi M, Moktefi A, et al. Renal Infarction and Its Consequences for Renal Function in Patients With Cardiac Amyloidosis.
Mayo Clin Proc. 2019;94(6):961-975.
Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879-2887.
Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799-2806.
Treibel TA, Fontana M, Maestrini V, et al. Automatic Measurement of the Myocardial Interstitium: Synthetic Extracellular Volume Quantification Without Hematocrit Sampling. JACC Cardiovasc Imaging. 2016;9(1):54-63.
Witteles RM, Bokhari S, Damy T, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019;7(8):709-716.

Signs and Symptoms That May Present in ATTR-CM1-14

AUTONOMIC

PERIPHERAL

Signs and Symptoms That May Present in ATTR-CM^1-14